Apollomics (APLM) Competitors $0.15 -0.01 (-6.26%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends APLM vs. CTMX, SCNX, LPTX, BYSI, CLRB, CELU, ALXO, IMRX, SPRO, and INCRShould you be buying Apollomics stock or one of its competitors? The main competitors of Apollomics include CytomX Therapeutics (CTMX), Scienture (SCNX), Leap Therapeutics (LPTX), BeyondSpring (BYSI), Cellectar Biosciences (CLRB), Celularity (CELU), ALX Oncology (ALXO), Immuneering (IMRX), Spero Therapeutics (SPRO), and InterCure (INCR). These companies are all part of the "pharmaceutical preparations" industry. Apollomics vs. CytomX Therapeutics Scienture Leap Therapeutics BeyondSpring Cellectar Biosciences Celularity ALX Oncology Immuneering Spero Therapeutics InterCure Apollomics (NASDAQ:APLM) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, risk, institutional ownership, analyst recommendations, earnings, dividends and community ranking. Does the media refer more to APLM or CTMX? In the previous week, CytomX Therapeutics had 3 more articles in the media than Apollomics. MarketBeat recorded 3 mentions for CytomX Therapeutics and 0 mentions for Apollomics. CytomX Therapeutics' average media sentiment score of 0.70 beat Apollomics' score of -0.25 indicating that CytomX Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Apollomics Neutral CytomX Therapeutics Positive Do institutionals and insiders believe in APLM or CTMX? 19.1% of Apollomics shares are held by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are held by institutional investors. 7.0% of CytomX Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has stronger earnings & valuation, APLM or CTMX? CytomX Therapeutics has higher revenue and earnings than Apollomics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioApollomics$1.22M13.34-$172.60MN/AN/ACytomX Therapeutics$101.21M0.67-$570K$0.175.12 Which has more risk & volatility, APLM or CTMX? Apollomics has a beta of 1.22, indicating that its stock price is 22% more volatile than the S&P 500. Comparatively, CytomX Therapeutics has a beta of 1.06, indicating that its stock price is 6% more volatile than the S&P 500. Does the MarketBeat Community believe in APLM or CTMX? CytomX Therapeutics received 368 more outperform votes than Apollomics when rated by MarketBeat users. However, 80.00% of users gave Apollomics an outperform vote while only 65.49% of users gave CytomX Therapeutics an outperform vote. CompanyUnderperformOutperformApollomicsOutperform Votes480.00% Underperform Votes120.00% CytomX TherapeuticsOutperform Votes37265.49% Underperform Votes19634.51% Do analysts prefer APLM or CTMX? Apollomics currently has a consensus target price of $2.00, suggesting a potential upside of 1,235.11%. CytomX Therapeutics has a consensus target price of $5.77, suggesting a potential upside of 563.43%. Given Apollomics' stronger consensus rating and higher possible upside, equities analysts plainly believe Apollomics is more favorable than CytomX Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apollomics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00CytomX Therapeutics 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Is APLM or CTMX more profitable? CytomX Therapeutics has a net margin of 10.96% compared to Apollomics' net margin of 0.00%. Apollomics' return on equity of 0.00% beat CytomX Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ApollomicsN/A N/A N/A CytomX Therapeutics 10.96%-41.47%8.11% SummaryCytomX Therapeutics beats Apollomics on 10 of the 16 factors compared between the two stocks. Ad Crypto Swap Profits[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get Apollomics News Delivered to You Automatically Sign up to receive the latest news and ratings for APLM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APLM vs. The Competition Export to ExcelMetricApollomicsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.28M$6.44B$5.05B$8.82BDividend YieldN/A8.11%5.17%4.07%P/E RatioN/A10.69125.6917.78Price / Sales13.34243.731,179.7874.25Price / CashN/A22.1633.7732.53Price / Book0.315.474.684.68Net Income-$172.60M$153.61M$119.54M$226.08M7 Day Performance37.43%-4.32%-2.46%-2.04%1 Month Performance16.94%-8.61%-4.08%0.06%1 Year Performance-81.28%28.79%29.82%24.60% Apollomics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APLMApollomics2.7369 of 5 stars$0.15-6.3%$2.00+1,235.1%-81.3%$17.85M$1.22M0.0045Gap DownHigh Trading VolumeCTMXCytomX Therapeutics4.3795 of 5 stars$0.87-2.2%$5.77+563.4%-37.4%$69.86M$101.21M5.12170Short Interest ↓SCNXScientureN/A$8.38+4.0%N/AN/A$69.13M$8.27M0.00N/ALPTXLeap Therapeutics2.3936 of 5 stars$2.59-4.1%$7.50+189.6%+25.1%$69.12M$1.50M0.0040Positive NewsBYSIBeyondSpringN/A$1.71-0.6%N/A+86.1%$66.74M$1.75M0.0080CLRBCellectar Biosciences2.4949 of 5 stars$1.56-3.1%$20.00+1,182.1%-27.8%$66.44MN/A-0.9110Analyst ForecastShort Interest ↓Analyst RevisionNews CoverageCELUCelularity0.5369 of 5 stars$2.94+0.7%N/A+42.7%$64.19M$22.77M0.00220News CoverageALXOALX Oncology3.3343 of 5 stars$1.21-1.6%$12.50+933.1%-87.7%$63.82MN/A-0.4140IMRXImmuneering3.1656 of 5 stars$2.04flat$12.80+527.5%-63.4%$63.34M$320,000.000.0060Analyst ForecastSPROSpero Therapeutics4.5933 of 5 stars$1.20+3.4%$5.00+316.7%-2.4%$63.24M$103.78M17.1546Analyst ForecastINCRInterCure1.2491 of 5 stars$1.33-3.6%N/A+16.0%$62.89M$96.61M0.00350Positive News Related Companies and Tools Related Companies CytomX Therapeutics Competitors Scienture Competitors Leap Therapeutics Competitors BeyondSpring Competitors Cellectar Biosciences Competitors Celularity Competitors ALX Oncology Competitors Immuneering Competitors Spero Therapeutics Competitors InterCure Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:APLM) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apollomics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apollomics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
